[Significance of interleukin 10 for acute graft versus host disease in children and adolescents after allogenic bone marrow transplantation].
BACKGROUND
It has been shown that Interleukin 10 (IL-10) is able to inhibit alloreactivity in a mixed lymphocyte culture. Therefore, here IL-10 production in patients after allogeneic BMT was investigated and correlated with the incidence of acute GvHD.


METHODS
14 patients after allogeneic BMT have been investigated. Patients' age ranged from 2.6 to 22 yrs. (median 7 yrs.). Patients were diagnosed with Ewing's sarcoma (1), ALL (4), AML (3), CML (2), Wiskott-Aldrich Syndrome (WAS;1), MDS (1) and SAA (2). GvHD > II degrees occurred in 5/14 patients. As control served 20 healthy volunteers.


METHODS
Mononuclear cells (MNC's) isolated from patients and 20 healthy controls were stimulated with an anti-CD3 monoclonal antibody for 72 hr. IL-10 was detected in cell-free supernatants by ELISA.


RESULTS
Anti-CD3-induced IL-10 production in MNC's isolated from patients (range/median: 0-1579 pg/10(6) MNC; 221 pg/10(6) MNC) was significantly reduced compared to healthy controls (160-5093 pg/10(6) MNC; 1250 pg/10(6) MNC; p < 0.01). 4/5 patients with low IL-10 production, but only 1/9 with a normal IL-10 production presented with GvHD > II degrees (p < 0.05).


CONCLUSIONS
Ex vivo IL-10 production was decreased in about one third of patients early after allogeneic BMT. The low IL-10 production was associated with a significantly increased risk of severe GvHD. Thus, supplementation of IL-10 might become a useful therapy to prevent GvHD.
Körholz
D
D
Klinik für Pädiatrische Hämatologie and Onkologie, Medizinische Einrichtungen der Heinrich-Heine-Universität, Düsseldorf.
Hempel
L
L
Packeisen
J
J
Kunst
D
D
Zintl
F
F
Burdach
S
S
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000276:immunology*; D006801:Humans; D016753:Interleukin-10 / Q000097:blood*; D007938:Leukemia / Q000276:immunology / Q000628:therapy*; D008297:Male; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D012307:Risk Factors
D016753:Interleukin-10